Multi-Subtype Vaccine Molecules for Broad Influenza Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional influenza vaccines are limited by their strain-specific nature, requiring time-consuming production and often failing to provide broad immunity against diverse influenza strains, especially due to antigenic drift and shifts.
Innovation Solution
A DNA vaccine formulation that targets hemagglutinin (HA) proteins from multiple influenza subtypes to major histocompatibility complex (MHC) class II molecules on antigen-presenting cells, inducing a mixture of HA proteins to enhance strain-specific and cross-protective antibody responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional influenza vaccines are used, then strain-specific immunity is achieved, but broad protection against diverse influenza strains is limited
Solution Approach 1:
The vaccine composition combines multiple HA proteins from different influenza subtypes (H1, H3, H5, H7, H9, H10) into a single formulation, enabling the vaccine to provide both strain-specific immunity against individual subtypes and broad cross-protection against diverse influenza strains, including those not explicitly included in the mixture
Solution Approach 2:
The patent merges six different HA proteins into one vaccine composition that can be administered simultaneously, consolidating what would traditionally require multiple separate vaccines into a single multi-functional preparation that addresses both specific and broad protection needs
2Productivity
If conventional vaccine production methods are used, then strain-specific vaccines are produced, but production time is substantial and production capacity is limited
Solution Approach 1:
The vaccine combines multiple HA proteins from different influenza subtypes into a single formulation that can be produced and administered together, eliminating the need for separate production lines and timing coordination for multiple individual vaccines, thereby substantially increasing production capacity and reducing time losses
3Adaptability or versatility
If DNA vaccines encoding multiple HA proteins are used, then broad immunity is induced, but vaccine complexity increases
Solution Approach 1:
The vaccine uses a universal approach by including HA proteins from six different influenza subtypes in a single composition, providing multi-functional protection that covers both current circulating strains and potential future variants, thereby achieving broad immunity through a standardized multi-component formulation rather than complex customized vaccines
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The vaccine mixture induces high titers of strain-specific antibodies and cross-reactive antibodies, providing protection against included and unrelated influenza strains, including unanticipated antigenic shifts.
Implementation Method 1
Each of the targeted DNA vaccines induced high titers of strain-specific anti-HA antibodies
Implementation Method 2
the vaccine mixture induced antibodies that cross-reacted with strains not included in the vaccine mixture
Data Source
AI summary
Provided herein is technology relating to vaccines and particularly, but not exclusively, to compositions, methods, and uses of a mixture of immunogenic vaccine molecules comprising components for targeting the dimeric vaccine molecules to antigen-presenting cells and components for eliciting an immunogenic response, wherein the components for eliciting an immunogenic response preferably comprise at least three variants of an immunogenic protein, such as variants of immunogenic proteins obtained from three or more different strains of a pathogenic organism.